pharmaphorum
JANUARY 9, 2022
US medical device company Abbott has said it plans to launch a new range of ‘biowearable’ health devices aimed at consumers, in a move that builds on its expertise in glucose monitoring. The company’s chief executive – Robert Ford – made the announcement at the massive CES tech trade show in Las Vegas, a venue usually dedicated to new TVs, gaming equipment, new smartphones and the like.
Outsourcing Pharma
JANUARY 12, 2022
The company plans to launch a Phase Ib/II study of its compound NVG-291 in collaboration with researchers at Northwestern Universityâs Shirley Ryan AbilityLab.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Healthcare
JANUARY 10, 2022
Investors poured record-breaking $29.1B into digital health startups. Will the momentum continue in 2022? hlandi. Mon, 01/10/2022 - 12:17.
Fossil Remedies
JANUARY 19, 2022
We know that the PCD Pharma Franchise business is lucrative and profitable. But do we know which PCD products should we pick so that the maximum profitability is ensured? Perhaps no. This blog is an attempt to clarify the concepts about choosing the best products. First, choose the right company. Experts say that one should choose an ISO-certified company that works as per the standards and guidelines laid by WHO and GMP.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Marketing Network
JANUARY 19, 2022
Talk to me. Pharma brands that want deep engagements need to look at and listen to social audio. It’s not surprising. In fact, it’s the most direct route to your goal. You want to talk to doctors? To start the conversation, we put pictures in front of them, bombarded them with videos, retarget them, and then send them emails. We want to talk, and they want to listen.
Pharma Times
JANUARY 5, 2022
The test is a technological first in determining the metastatic status of a cancer without using prior insight of the primary cancer presented.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Outsourcing Pharma
JANUARY 10, 2022
Joining with a noted research foundation, the group is aiming for earlier detection and treatment of the disease, which hits nearly 500K people annually.
Fierce Healthcare
JANUARY 21, 2022
Global digital health funding skyrockets to $57.2B with record cash for mental health, telehealth. hlandi. Fri, 01/21/2022 - 11:17.
pharmaphorum
JANUARY 19, 2022
Just months after the venture was unveiled, controversial biotechnology company Altos Labs has officially launched with $3 billion in funding secured from investors. Dubbed an ‘anti-ageing’ company, Altos has gained mainstream attention for its focus on ‘rejuvenation’ and biological reprogramming technology. While the specific research goals have been kept a closely guarded secret, some scientists propose that rejuvenating cells in a lab could be a path to prolonging huma
pharmaphorum
JANUARY 14, 2022
Japanese pharma group Otsuka has led a $10 million first-round financing of GrayMatters Health, an Israeli company developing a digital health approach to the management of mental illness. Otsuka Medical Devices is also taking some rights to GrayMatters’ platform – called Prism – in Japan and some other Asian countries in connection with the financing, which was supported by Joy Ventures, J-Ventures, J-Impact, and existing backers Marius Nacht and Joyance Ventures.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JANUARY 12, 2022
Roche has launched what it says is a first-of-its kind handheld glucose management device, backed up by a digital platform that aims to simplify the work of doctors and nurses as they deliver care to patients. The cobas pulse system is a point-of-care device that combines a glucose test strip reader with a touch screen that is used for displaying patient information and data, as well as analysing and sharing clinical results.
pharmaphorum
JANUARY 14, 2022
The European Commission, EMA and national regulators within the EU have launched an initiative to change the way clinical trials are designed and run in order to position the bloc as an international “focal point” for clinical research. The broad strokes of the proposals are laid out in a document entitled Accelerating Clinical Trials in the EU (ACT EU) that lists priority actions that will be taken, including measures to allow greater use of innovative clinical trial designs.
pharmaphorum
JANUARY 11, 2022
With evidence growing that the current crop of COVID-19 vaccines are less protective against infection with Omicron, both Pfizer and Moderna have announced plans to develop new versions of their mRNA-based shots that are tailored to the new variant. Pfizer has said that a COVID-19 jab specifically targeting Omicron, as well as other existing variants, will begin human trials later this month and could be available as early as March.
pharmaphorum
JANUARY 5, 2022
A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial. The new vaccine differs from the currently approved shots because it delivers antigens for both the spike protein and other proteins found in SARS-CoV-2.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
JANUARY 26, 2022
Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology. The US regulator cleared the company’s lead TCR Kimmtrak (tebentafusp; formerly IMCgp100 ) – a bispecific T cell engager (BiTE) that consists of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes – as a treatment for unresectable or metastatic uveal me
pharmaphorum
JANUARY 17, 2022
After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics. Under the joint research plan, the Danish giant will work with EraCal to identify novel drug targets relevant for food intake regulation and additional metabolic phenotypes. Although specific details of the collaboration are yet to be released, EraCal has confirmed that the duo will utilise its phenotypic drug discovery platform to id
Fierce Healthcare
JANUARY 13, 2022
Supreme Court upholds HHS' vaccine requirement for healthcare workers, blocks OSHA's large employer mandate. dmuoio. Thu, 01/13/2022 - 15:37.
Fierce Healthcare
JANUARY 7, 2022
CMS issued over 300 warnings, but no fines, to hospitals falling short on price transparency last year. dmuoio. Fri, 01/07/2022 - 17:39.
pharmaphorum
JANUARY 24, 2022
In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease. pharmaphorum caught up with AZ’s Joris Silon to discuss unmet needs in the condition. “Many times, I have talked to nephrologists who take care of patients with chronic kidney disease in the later stages, and they have a very simple message – and that is, if we really want to do something for these patients then we need to intervene earlier,” says Joris Silon, se
pharmaphorum
JANUARY 18, 2022
Microsoft and CVS Health have announced a new strategic alliance focusing on personalised care and accelerating digital transformation for the benefit of CVS customers and its employees. David Rhew, MD, global chief medical officer and VP of healthcare at Microsoft, tells us, “Using Microsoft technology, CVS Health will develop a more agile, digital-first technology foundation.” Digital innovation and implementation have skyrocketed within healthcare due to the need to adapt quickly
Fierce Healthcare
JANUARY 19, 2022
Fierce JPM Week: Women are the 'power buyers' of healthcare. Here's how to serve them better. hlandi. Wed, 01/19/2022 - 13:54.
pharmaphorum
JANUARY 17, 2022
GlaxoSmithKline (GSK) claims it has rejected three unsolicited, conditional and non-binding proposals from Unilever to acquire GSK Consumer Healthcare in a deal worth approximately $68.4 billion (£50 billion). The Consumer Healthcare business is a Joint Venture between GSK and Pfizer, with GSK holding a majority controlling interest of 68% and Pfizer 32%.
Fierce Healthcare
JANUARY 10, 2022
Facing understaffed hospitals, California temporarily allows asymptomatic workers to return after positive COVID test, exposure. dmuoio. Mon, 01/10/2022 - 13:27.
Fierce Healthcare
JANUARY 21, 2022
Cigna study: Virtual care can reduce unnecessary ER, urgent care visits by 19%. pminemyer. Fri, 01/21/2022 - 14:24.
Fierce Healthcare
JANUARY 10, 2022
JPM 2022: Aledade scoops up advance care planning startup Iris Healthcare to build out health services unit. hlandi. Mon, 01/10/2022 - 20:53.
pharmaphorum
JANUARY 17, 2022
A World Health Organization (WHO) panel has given the green light to two new drugs to treat COVID-19. US-based Eli Lilly’s baricitinib (Olumiant), a Janus kinase inhibitor, and GlaxoSmithKline and Vir Biotechnology’s sotrovimab, a monoclonal antibody, were recommended in new WHO guidelines, published in the British Medical Journal. . Baricitinib, administered with corticosteroids, was strongly recommended as a treatment for patients with severe or critical illness.
pharmaphorum
JANUARY 7, 2022
AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months. In the latest deal, the pharma group is paying $30 million upfront with another $730 million in milestone’s for global rights to Neurimmune’s NI006, a drug in early-stage clinical for cardiomyopathy, a progressive and fatal complication affecting some patients with ATTR.
pharmaphorum
JANUARY 6, 2022
We spoke with Tanja Dowe, ahead of the annual J.P. Morgan Health Care Conference 2022, about radical innovation in healthcare, including the potential of digital solutions to diagnose disease earlier, using digital therapeutics or preventive digital solutions more efficiently, and making use of technologies that result in accelerated drug discovery and development.
pharmaphorum
JANUARY 21, 2022
A third dose of vaccine has been shown to effectively neutralise the Omicron variant of covid-19, according to researchers. Research led by UCLH, UCL and the Francis Crick Institute found that the booster dose successfully stimulates antibody levels that neutralise Omicron. Details of the study were published in The Lancet this week. UCLH researchers stated that antibodies generated in people who had received only two doses of either the Oxford/AstraZeneca vaccine or the Pfizer/BioNTech vaccin
Fierce Healthcare
JANUARY 6, 2022
Forrester: Here are 4 key frontiers for healthcare innovation over the next decade. pminemyer. Thu, 01/06/2022 - 12:54.
Fierce Healthcare
JANUARY 5, 2022
Magellan Healthcare, NeuroFlow team up on digital mental health program for members. agliadkovskaya. Wed, 01/05/2022 - 18:58.
Fierce Healthcare
JANUARY 18, 2022
Microsoft, Cleveland Clinic and Providence join coalition to innovate AI in healthcare. rtorrence. Tue, 01/18/2022 - 11:32.
Fierce Healthcare
JANUARY 18, 2022
Study: Insurers spend nearly $130M a year on ivermectin prescriptions. pminemyer. Tue, 01/18/2022 - 16:23.
pharmaphorum
JANUARY 28, 2022
Merck & Co has passed another milestone in its drive to move PD-1 inhibitor Keytruda earlier in the treatment pathway for cancer, with the European Commission approving use of the drug as post-surgery (adjuvant) therapy for renal cell carcinoma (RCC). Adjuvant treatment moves use of the drug into patients with earlier-stage cancer, a key strategy for Merck and other cancer immunotherapy companies as it expands the pool of patients eligible for treatment.
Expert insights. Personalized for you.
145 
Let's personalize your content